Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents

Silvia S. Chiang; Jennifer J. Furin

doi:10.1055/s-0037-1607234

Journal of Pediatric Infectious Diseases, Table of Contents

J Pediatr Infect Dis 2018; 13(02): 153-168
DOI: 10.1055/s-0037-1607234

Review Article

Georg Thieme Verlag KG Stuttgart · New York

Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents

Silvia S. Chiang

¹Department of Pediatrics, Alpert Medical School of Brown University, Providence, Rhode Island, United States

²Center for International Health Research, Rhode Island Hospital, Providence, Rhode Island, United States

,

Jennifer J. Furin

³Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts United States

› Author Affiliations

Abstract

Although tens of thousands of children and adolescents become sick with multidrug-resistant tuberculosis (MDR-TB) each year, fewer than 1,500 cases documenting treatment have been reported in the literature. Children treated for MDR-TB tend to have excellent clinical outcomes, but they suffer from the adverse events associated with current management strategies. This article will review the recommendations, evidence base, and future directions for MDR-TB therapy in children and adolescents.

Keywords

multidrug-resistant tuberculosis - extensively drug-resistant tuberculosis - antitubercular agents - children - adolescents

Full Text

References

References
1 World Health Organization. Global Tuberculosis Report 2016. Geneva, Switzerland: World Health Organization; 2016
2 McBryde ES, Meehan MT, Doan TN. , et al. The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains. Int J Infect Dis 2017; 56: 14-20
3 World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update. Geneva, Switzerland: World Health Organization; 2016
4 Jenkins HE, Tolman AW, Yuen CM. , et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 2014; 383 (9928): 1572-1579
5 Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis 2016; 16 (10) 1193-1201
6 Chiang SS, Starke JR, Miller AC. , et al. Baseline predictors of treatment outcomes in children with multidrug-resistant tuberculosis: a retrospective cohort study. Clin Infect Dis 2016; 63 (08) 1063-1071
7 Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12 (06) 449-456
8 Gegia M, Jenkins HE, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis 2013; 17 (05) 624-629
9 Moore BK, Anyalechi E, van der Walt M. , et al. Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa, 2005-2010. Int J Tuberc Lung Dis 2015; 19 (06) 663-669
10 Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 2014; 69 (05) 458-464
11 Marais BJ, Gie RP, Schaaf HS. , et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004; 8 (04) 392-402
12 Garcia-Prats AJ, Draper HR, Thee S. , et al. Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. Antimicrob Agents Chemother 2015; 59 (10) 6073-6079
13 Thee S, Detjen AA, Wahn U, Magdorf K. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scand J Infect Dis 2010; 42 (04) 294-298
14 Thee S, Garcia-Prats AJ, McIlleron HM. , et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob Agents Chemother 2014; 58 (05) 2948-2951
15 Thee S, Seddon JA, Donald PR. , et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 2011; 55 (12) 5560-5567
16 Thee S, Seifart HI, Rosenkranz B. , et al. Pharmacokinetics of ethionamide in children. Antimicrob Agents Chemother 2011; 55 (10) 4594-4600
17 Verhagen LM, López D, Hermans PW. , et al. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. Trop Med Int Health 2012; 17 (12) 1449-1456
18 Isaakidis P, Paryani R, Khan S. , et al. Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India. PLoS One 2013; 8 (07) e68869
19 Moyo S, Furin JJ, Hughes J. , et al. Outcomes in adolescents undergoing treatment for drug-resistant tuberculosis in Cape Town, South Africa, 2008-2013. Arch Pediatr Infect Dis 2014; 3: e17934
20 Tierney DB, Milstein MB, Manjourides J, Furin JJ, Mitnick CD. Treatment outcomes for adolescents with multidrug-resistant tuberculosis in Lima, Peru. Glob Pediatr Health 2016; 3: X16674382
21 Smirnova PA, Turkova A, Nikishova EI. , et al. Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study. Eur Respir J 2016; 48 (05) 1496-1499
22 Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis 2002; 6 (12) 1038-1045
23 Chiang SS, Swanson DS, Starke JR. New diagnostics for childhood tuberculosis. Infect Dis Clin North Am 2015; 29 (03) 477-502
24 World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva, Switzerland: World Health Organization; 2014
25 World Health Organization. Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children. Geneva, Switzerland: World Health Organization; 2013
26 Mukherjee JS, Rich ML, Socci AR. , et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363 (9407): 474-481
27 Rich ML, Seung KJ. The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis. Boston, MA, U.S.A.: Partners In Health; 2013
28 Caminero JA. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease (The Union); 2013
29 Furin J, Seddon JA, Perez-Velez CM. , et al. Management of Drug-Resistant Tuberculosis in Children: a Field Guide. 2nd ed. Boston, USA: The Sentinel Project for Pediatric Drug-Resistant Tuberculosis; 2015
30 Falzon D, Jaramillo E, Schünemann HJ. , et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38 (03) 516-528
31 Chang KC, Yew WW, Tam CM, Leung CC. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57 (09) 4097-4104
32 Payen MC, De Wit S, Martin C. , et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16 (04) 558-560
33 Brigden G, Hewison C, Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist 2015; 8: 367-378
34 World Health Organization. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, Switzerland: World Health Organization; 2014
35 World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Guidance. Geneva, Switzerland: World Health Organization; 2013
36 World Health Organization. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents: Interim Policy Guidelines. Geneva, Switzerland: World Health Organization; 2016
37 Hafkin J, Frias M, DeLeon A. , et al. Long-term safety, tolerability, and pharmacokinetics of delamanid in pediatric MDR-TB patients, ages 12–17 years. Abstract presented at: 46th Union World Conference on Lung Health, 2015 Dec 2–6, 2015 ; Cape Town, South Africa
38 Hafkin J, Frias M, Hesseling A. , et al. Pharmacokinetics and safety of delamanid in pediatric MDR-TB patients, ages 6–17 years. Abstract presented at: International Conference on Antimicrobial Agents and Chemotherapy, 2015 Sep 18–21; San Diego, U.S.A.
39 ClinicalTrials.gov. 2017 . Available at: https://clinicaltrials.gov/show/NCT01859923 . Accessed March 17, 2017
40 Tadolini M, Garcia-Prats AJ, D'Ambrosio L. , et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 2016; 48 (03) 938-943
41 Harausz EP, Garcia-Prats AJ, Seddon JA. , et al; Sentinel Project on Pediatric Drug-Resistant Tuberculosis. New/repurposed drugs for pediatric multidrug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2017; 195 (10) 1300-1310
42 World Health Organization. A 2016 Review of Available Evidence on the Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2017
43 Wiseman CA, Gie RP, Starke JR. , et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J 2012; 31 (04) 347-352
44 Achar J, Berry C, Herboczek K. , et al. Multidrug-resistant tuberculosis in child successfully treated with 9-month drug regimen. Emerg Infect Dis 2015; 21 (11) 2105-2106
45 Thomas TA, Shenoi SV, Heysell SK. , et al. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. Int J Tuberc Lung Dis 2010; 14 (10) 1244-1251
46 Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis 2012; 16 (12) 1588-1593
47 Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb) 2014; 94 (02) 93-104
48 Salazar-Austin N, Ordonez AA, Hsu AJ. , et al. Extensively drug-resistant tuberculosis in a young child after travel to India. Lancet Infect Dis 2015; 15 (12) 1485-1491
49 Guglielmetti L, Jaspard M, Le Dû D. , et al; French MDR-TB Management Group. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49 (03) 1601799
50 Lee M, Lee J, Carroll MW. , et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367 (16) 1508-1518
51 Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H. Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 2015; 373 (03) 291-292
52 Schaaf HS, Michaelis IA, Richardson M. , et al. Adult-to-child transmission of tuberculosis: household or community contact?. Int J Tuberc Lung Dis 2003; 7 (05) 426-431
53 Schaaf HS, Van Rie A, Gie RP. , et al. Transmission of multidrug-resistant tuberculosis. Pediatr Infect Dis J 2000; 19 (08) 695-699
54 Seddon JA, Furin JJ, Gale M. , et al; Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186 (10) 953-964
55 Harausz EP, Garcia-Prats AJ, Schaaf HS. , et al. Global treatment outcomes in children with paediatric MDR-TB: systematic review and meta-analysis. Abstract presented at: 46th Union World Conference on Lung Health; December 2–6, 2015 ; Cape Town, South Africa
56 Pepper DJ, Marais S, Wilkinson RJ. , et al. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis 2010; 10: 83
57 Graham SM, Coulter JB, Gilks CF. Pulmonary disease in HIV-infected African children. Int J Tuberc Lung Dis 2001; 5 (01) 12-23
58 Graham SM. Non-tuberculosis opportunistic infections and other lung diseases in HIV-infected infants and children. Int J Tuberc Lung Dis 2005; 9 (06) 592-602
59 Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 2003; 88 (12) 1106-1111
60 Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293 (22) 2732-2739
61 Drobac PC, Mukherjee JS, Joseph JK. , et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117 (06) 2022-2029
62 Méndez Echevarría A, Baquero Artigao F, García Miguel MJ. , et al. [Multidrug-resistant tuberculosis in the pediatric age group]. An Pediatr (Barc) 2007; 67 (03) 206-211
63 Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis 2011; 11: 28
64 Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54 (02) 157-166
65 Hicks RM, Padayatchi N, Shah NS. , et al. Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children. Int J Tuberc Lung Dis 2014; 18 (09) 1074-1083
66 Organization WH. Definitions and Reporting Framework for Tuberculosis – 2013 Revision. Geneva, Switzerland: World Health Organization; 2013
67 Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health 2009; 14 (11) 1329-1337
68 Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect 2013; 66 (04) 320-329
69 Peloquin CA, Berning SE, Nitta AT. , et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38 (11) 1538-1544
70 Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother 2015; 59 (10) 6337-6343
71 Thee S, Zöllner EW, Willemse M, Hesseling AC, Magdorf K, Schaaf HS. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis 2011; 15 (09) 1191-1193 , i
72 Starke JR. Tuberculosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS. , eds. 2015 Report of the Committee on Infectious Diseases, 30th ed. Elk Grove Village, IL, U.S.A.: American Academy of Pediatrics; 2015: 805-831
73 List of Products Available. 2017 . Available at: www.stoptb.org/gdf/drugsupply/pc2.asp?CLevel=2&CParent=4 . Accessed March 14, 2017
74 Furin J, Mafukidze A, Brigden G. , et al. A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children. Int J Tuberc Lung Dis 2015; 19 (Suppl. 01) 55-60
75 Taneja R, Garcia-Prats AJ, Furin J, Maheshwari HK. Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations. Int J Tuberc Lung Dis 2015; 19 (Suppl. 01) 61-68
76 du Cros P, Swaminathan A, Bobokhojaev OI. , et al. Challenges and solutions to implementing drug-resistant tuberculosis programmes for children in Central Asia. Public Health Action 2015; 5 (02) 99-102
77 Chiang SS, Roche S, Contreras C. , et al. Barriers to the treatment of childhood tuberculous infection and tuberculosis disease: a qualitative study. Int J Tuberc Lung Dis 2017; 21 (02) 154-160
78 PEDDTB. 2017 . Available at: www.healthadvocacyinnovations.org/peddtb/ . Accessed March 14, 2017
79 Furin J, Brigden G, Lessem E, Becerra MC. Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study. Int J Tuberc Lung Dis 2013; 17 (09) 1239-1241
80 Brigden G, Furin J, Van Gulik C, Marais B. Getting it right for children: improving tuberculosis treatment access and new treatment options. Expert Rev Anti Infect Ther 2015; 13 (04) 451-461
81 Usherenko I, Basu Roy U, Mazlish S. , et al. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions. Int J Tuberc Lung Dis 2015; 19 (Suppl. 01) 23-31
82 Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis (Edinb) 2015; 95 (03) 229-245
83 Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infect Drug Resist 2015; 8: 359-366
84 Franck C, Seddon JA, Hesseling AC, Schaaf HS, Skinner D, Reynolds L. Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. BMC Infect Dis 2014; 14: 426
85 Brust JC, Shah NS, Scott M. , et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16 (08) 998-1004
86 Benbaba S, Isaakidis P, Das M, Jadhav S, Reid T, Furin J. Direct observation (DO) for drug-resistant tuberculosis: do we really DO?. PLoS One 2015; 10 (12) e0144936
87 Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17 (03) 299-307
88 Shin S, Furin J, Bayona J, Mate K, Kim JY, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004; 59 (07) 1529-1539
89 Tupasi TE, Garfin AM, Kurbatova EV. , et al. Factors associated with loss to ffollow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012–2014. Emerg Infect Dis 2016; 22 (03) 491-502
90 Task Force Update. 2016 . Available at: www.stoptb.org/wg/mdrtb/taskforces.asp?tf=4 . Accessed March 7, 2017
91 Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S. Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis. Emerg Infect Dis 2016; 22 (03) 22
92 Seddon JA, McKenna L, Shah T, Kampmann B. Recent developments and future opportunities in the treatment of tuberculosis in children. Clin Infect Dis 2015; (61) (Suppl. 03) S188-S199
93 Protection of human subjects; Belmont Report: notice of report for public comment. Fed Regist 1979; 44 (76) 23191-23197
94 Nachman S, Ahmed A, Amanullah F. , et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015; 15 (06) 711-720
95 Study 2005. 2017 . Available at: www.impaactnetwork.org/studies/-devel . Accessed March 7, 2017
96 Weld E, Garcia-Prats AJ, Furin J, Bailey T, Hesseling A, Dooley K. The time has come: the case for injectable-sparing regimens in children with multidrug-resistant tuberculosis. Lancet Respir Med 2017; 5: 245-246 . doi:10.1016/s2213-2600(17)30078-4
97 Velayutham B, Nair D, Ramalingam S, Perez-Velez CM, Becerra MC, Swaminathan S. Setting priorities for a research agenda to combat drug-resistant tuberculosis in children. Public Health Action 2015; 5 (04) 222-235
98 Kristina F, McNelley E, Tran CS, Burzynski J, Saiman L. Management of Pediatric Multidrug-Resistant Tuberculosis and Latent Tuberculosis Infections in New York City From 1995 to 2003. Pediatr Infect Dis J 2008; 27 (10) 907-912
99 Leimane V, Riekset Altina V, Holtz TH. , et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326
100 Seddon JA, Hesseling AC. , M, et al. Culture-Confirmed Multidrug-Resistant Tuberculosis in Children: Clinical Features, Treatment, and Outcome. Clin Infect Dis 2012; 54 (02) 157-166